HealthCare Royalty Partners
Overview
HealthCare Royalty Partners is a global healthcare investment firm that purchases royalties and uses debt-like structures to invest in commercial or near-commercial stage biopharmaceutical assets.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Apnimed | Mar 2026 | Debt | Lead |
| Xiasma Limited | Apr 2020 | Debt | Lead |
| Spero Biopharma | Jul 2026 | Debt | Lead |
| TheracosBio | Aug 2023 | Debt | Co-investor |
| Suneva Medical | Jun 2016 | Growth Equity | Co-investor |
For institutional investors. Book with your work email.
Key People
Greg Brown
Founder & Member, Senior Advisor Board
Clarke Futch
Founder, Chairman & Chief Executive Officer
John Urquhart
Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is HealthCare Royalty Partners based?
HealthCare Royalty Partners is headquartered in Stamford, Connecticut, United States.
When was HealthCare Royalty Partners founded?
HealthCare Royalty Partners was founded in 2007.
How many portfolio companies does HealthCare Royalty Partners have?
HealthCare Royalty Partners has 6 portfolio companies in Caplight's dataset.
What are some companies in HealthCare Royalty Partners's portfolio?
Portfolio companies visible on Caplight include Apnimed, Xiasma Limited, Spero Biopharma, TheracosBio, Suneva Medical.
What was HealthCare Royalty Partners's most recent investment shown here?
HealthCare Royalty Partners's most recent investment in this portfolio sample was in Spero Biopharma in 2026.
What sectors does HealthCare Royalty Partners focus on?
HealthCare Royalty Partners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software.
What company stages does HealthCare Royalty Partners focus on?
HealthCare Royalty Partners typically invests at the MultiStage stage.
What is HealthCare Royalty Partners's AUM?
HealthCare Royalty Partners's assets under management are estimated between $3.8B and $3.8B.